News | May 27, 2022
Torrent Pharma acquires four brands from Dr Reddy’s
The integration and transition of the brands are expected to be completed by June 2022.
The integration and transition of the brands are expected to be completed by June 2022.
He has extensive leadership experience across supply chain and has worked at companies such as Unilever, Flipkart, Colgate-Palmolive & Mondelez
The entire integration and transition of the brands is expected to be completed by March 2022
The Vasostrict brand market had U.S. sales of approximately US $ 878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
The company will market it under the brand name Molflu
The tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
Subscribe To Our Newsletter & Stay Updated
